Peregrine Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $8.26M | Sell |
|
|||||
|
2025
Q2 | $8.43M | Sell |
|
|||||
|
2025
Q1 | $8.07M | Buy |
|
|||||
|
2024
Q4 | $8.85M | Buy |
|
|||||
|
2024
Q3 | $7.34M | Sell |
|
|||||
|
2024
Q2 | $9.31M | Buy |
|
|||||
|
2024
Q1 | $9.21M | Sell |
|
|||||
|
2023
Q4 | $8.89M | Sell |
|
|||||
|
2023
Q3 | $8.9M | Sell |
|
|||||
|
2023
Q2 | $8.8M | Buy |
|
|||||
|
2023
Q1 | $8.56M | Buy |
|
|||||
|
2022
Q4 | $8.12M | Sell |
|
|||||
|
2022
Q3 | $9.11M | Sell |
|
|||||
|
2022
Q2 | $8.9M | Sell |
|
|||||
|
2022
Q1 | $8.57M | Sell |
|
|||||
|
2021
Q4 | $8.34M | Buy |
|